Acute optic neuritis: a clinical paradigm for evaluation of neuroprotective and restorative strategies?

by Sara S Qureshi, Elliot M Frohman
Published 2015-01-01

Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis

by J. Theodore Phillips, Elliot M. Frohman
Published 2008-11-01

From injection therapies to natalizumab: views on the treatment of multiple sclerosis

by Roberto Bomprezzi, Darin T. Okuda, Yazan J. Alderazi, Olaf Stüve, Elliot M. Frohman
Published 2012-03-01

Current and emerging therapies in multiple sclerosis: a systematic review

by Wanda Castro-Borrero, Donna Graves, Teresa C. Frohman, Angela Bates Flores, Paula Hardeman, Diana Logan, Megan Orchard, Benjamin Greenberg, Elliot M. Frohman
Published 2012-07-01

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in e...

by Gina M. Remington, Katherine Treadaway, Teresa Frohman, Amber Salter, Olaf Stüve, Michael K. Racke, Kathleen Hawker, Federica Agosta, Maria Pia Sormani, Massimo Filippi, Elliot M. Frohman
Published 2010-01-01

PEG minocycline-liposomes ameliorate CNS autoimmune disease.

by Wei Hu, Josbert Metselaar, Li-Hong Ben, Petra D Cravens, Mahendra P Singh, Elliot M Frohman, Todd N Eagar, Michael K Racke, Bernd C Kieseier, Olaf Stüve
Published 2009-01-01

The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials.

by Christina V Warner, Stephanie B Syc, Aleksandra M Stankiewicz, Girish Hiremath, Sheena K Farrell, Ciprian M Crainiceanu, Amy Conger, Teresa C Frohman, Esther R Bisker, Laura J Balcer, Elliot M Frohman, Peter A Calabresi, Shiv Saidha
Published 2011-01-01

Symptomatic therapy in multiple sclerosis

by Teresa C. Frohman, Wanda Castro, Anjali Shah, Ardith Courtney, Jeffrey Ortstadt, Scott L. Davis, Diana Logan, Thomas Abraham, Jaspreet Abraham, Gina Remington, Katherine Treadaway, Donna Graves, John Hart, Olaf Stuve, Gary Lemack, Benjamin Greenberg, Elliot M. Frohman
Published 2011-03-01

A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients

by Ann J. Ligocki, Jacqueline R. Rivas, William H. Rounds, Alyssa A. Guzman, Min Li, Melania Spadaro, Lauren Lahey, Ding Chen, Paul M. Henson, Donna Graves, Benjamin M. Greenberg, Elliot M. Frohman, E. Sally Ward, William Robinson, Edgar Meinl, Charles L. White, Ann M. Stowe, Nancy L. Monson
Published 2015-10-01

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple scler...

by Elliot M. Frohman, Gary Cutter, Gina Remington, Hongjiang Gao, Howard Rossman, Bianca Weinstock-Guttman, Jacqueline E. Durfee, Amy Conger, Ellen Carl, Katherine Treadaway, Eric Lindzen, Amber Salter, Teresa C. Frohman, Anjali Shah, Angela Bates, Jennifer L. Cox, Michael G. Dwyer, Olaf Stuve, Benjamin M. Greenberg, Michael K. Racke, Robert Zivadinov
Published 2010-01-01